– Thomas Reith succeeds Dr. Fridtjof Traulsen
– IT expert aims to drive digital transformation

The largest research and development site of Boehringer Ingelheim is getting a new site manager: Thomas Reith will take over from Dr. Fridtjof Traulsen on April 15th in Biberach, who took over the chairman…

– Strategically important investment at the site
– Facility with high flexibility for the production of chemical, innovative active ingredients
– Future sustainable production with green hydrogen planned

Boehringer Ingelheim is investing in the production of active ingredients at the Germany site: The…

Biopharmaceuticals are the foundation for many new therapeutic approaches – and at the same time, great hope for numerous patients. They contain the potential to address previously untreatable diseases in a highly targeted manner. However, the work on these diverse active substances, from research t…

– Investment of 350 million EUR in state-of-the-art research infrastructure is Boehringer Ingelheim’s largest single investment in Germany to date
– Boehringer Ingelheim strengthens innovation power and development of biopharmaceuticals, which account for approx. 50 percent of the company’s research…